Twist Bioscience Unveils Stellar 2QFY25 Results, Spins Off DNA Data Storage

SOUTH SAN FRANCISCO, Calif. -- (May 5, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) has just dropped its fiscal second quarter 2025 earnings report, and it?s looking like a banner quarter for the biotech firm. With a revenue forecast hitting an impressive $92.8 million, up 23% from $75.3 million in the same quarter last year, this isn't just a run-of-the-mill earnings surprise; it?s a growth spurt that even a teenager would envy. Investors are likely to be pleased, especially considering this marks the ninth consecutive quarter of sequential growth.

Revenue Breakdown: The Numbers Tell a Story

Breaking down the revenue, we see that the SynBio segment grew 21% to $36 million, while NGS revenue surged by 25% to $51.1 million. Biopharma wasn?t left behind either, climbing 21% to $5.7 million. It?s almost like Twist is saying, ?Why stop at one growth driver when you can have three??

Margins & Expenses: Picking Up Steam

Gross margin also saw a notable uptick, reaching 49.6% compared to 41% in the same period last year. This 8.6 percentage point improvement is not just a feather in their cap; it?s a full-on plume. On the flip side, selling, general, and administrative expenses rose to $63.7 million, partly due to a $5.3 million increase in non-cash stock-based compensation. It seems the company is investing in its own future while still managing to keep an eye on profitability.

Adjusted EBITDA and Future Outlook

Twist is projecting adjusted EBITDA breakeven by the end of fiscal 2026, which could be a game-changer for the company and its shareholders. The EPS consensus may not reflect this yet, but if they hit this target, it could send the stock soaring. Investors love to see a path to profitability, especially in the biotech sector, where timelines can stretch into infinity.

Additionally, the company has announced the spinout of its DNA storage application as an independent entity, Atlas Data Storage, backed by a hefty $155 million investment from a consortium that includes ARCH Venture Partners and Bezos Expeditions. This strategic move could allow Twist to sharpen its focus on its core offerings while simultaneously fueling the growth of the burgeoning DNA data storage market. Talk about a win-win!

What This Means for the Sector

So, what does this all mean for Twist and its sector peers? The solid earnings report could set a precedent for other biotech firms looking to demonstrate growth and profitability amidst a landscape often riddled with uncertainty. As companies like Twist continue to innovate and expand their market share, it may signal a resurgence of investor confidence in the biotech sector.

With the earnings surprise, robust revenue growth, and a clear path toward adjusted EBITDA breakeven, Twist is not just participating in the biotech boom; it?s leading the charge. As the company continues to navigate this complex landscape, it will be interesting to watch how it capitalizes on its momentum and whether other companies will follow suit.